Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported E.P.S. of $-1.36 for its fourth fiscal quarter (ending September 30) versus $-1.33 for the same period a year ago — an increase of 2%. E.P.S. were $-5.48 for the latest four quarters through September 30 versus $-6.38 for the same period a year ago — a decline of -14%.
Recent Price Action
On 11/25/24, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) stock declined by -3.5%, closing at $9.01. This decline was accompanied by normal trading volume. Relative to the market the stock has been weak over the last nine months and has declined -5.5% during the last week.
Current PriceTarget Research Rating
Enanta Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Enanta Pharmaceuticals has a slightly negative Appreciation Score of 32 and a poor Power Rating of 25, producing the Lowest Value Trend Rating.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment